Revenues - Narrative (Details) - Santen Pharmaceutical Co. Ltd. $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Exercise of option to expand the territories to include Russia
Disaggregation of Revenue [Line Items]
Upfront cash payment	$ 2.0
Developmental and regulatory cash milestone payments	1.0
Maximum
Disaggregation of Revenue [Line Items]
Developmental and regulatory cash milestone payments	1.0
License Agreement
Disaggregation of Revenue [Line Items]
Upfront cash payment	$ 15.5
Period of option to expand territories following amendment date	5 years